Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Diamedica Therapeutics Inc (DMAC)
Diamedica Therapeutics Inc (DMAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,519
  • Shares Outstanding, K 37,954
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,680 K
  • 60-Month Beta 1.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.05
Trade DMAC with:

Options Overview Details

View History
  • Implied Volatility 297.51% ( +210.34%)
  • Historical Volatility 54.58%
  • IV Percentile 95%
  • IV Rank 51.36%
  • IV High 550.87% on 03/22/23
  • IV Low 29.98% on 02/05/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 5
  • Volume Avg (30-Day) 86
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 1,383
  • Open Int (30-Day) 680

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.14
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.79 +10.04%
on 02/26/24
3.30 -6.98%
on 02/06/24
+0.07 (+2.33%)
since 02/01/24
3-Month
2.53 +21.34%
on 12/04/23
3.30 -6.98%
on 02/06/24
+0.48 (+18.53%)
since 12/01/23
52-Week
1.46 +110.27%
on 03/31/23
4.75 -35.37%
on 06/26/23
+1.30 (+73.45%)
since 03/01/23

Most Recent Stories

More News
Three (3) Stocks Under $10 That Insiders Are Buying 

These small-cap names provide an opportunity that insiders are buying including deep value, growth, new technology, and AI.

DMAC : 3.07 (+2.33%)
ADT : 7.30 (+0.55%)
CMTL : 6.60 (-2.37%)
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today...

DMAC : 3.07 (+2.33%)
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David...

DMAC : 3.07 (+2.33%)
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 3.07 (+2.33%)
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today...

DMAC : 3.07 (+2.33%)
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...

DMAC : 3.07 (+2.33%)
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment...

DMAC : 3.07 (+2.33%)
KPTI : 1.1850 (+2.16%)
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 3.07 (+2.33%)
DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...

DMAC : 3.07 (+2.33%)
What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock

DiaMedica Therapeutics, Inc. (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

DMAC : 3.07 (+2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada....

See More

Key Turning Points

3rd Resistance Point 3.36
2nd Resistance Point 3.26
1st Resistance Point 3.16
Last Price 3.07
1st Support Level 2.96
2nd Support Level 2.86
3rd Support Level 2.76

See More

52-Week High 4.75
Fibonacci 61.8% 3.49
Fibonacci 50% 3.11
Last Price 3.07
Fibonacci 38.2% 2.72
52-Week Low 1.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar